Santero Therapeutics

What Santero Therapeutics does

Santero Therapeutics is a Belgian preclinical biotechnology company founded in 2021 as a spin-off from the Université Libre de Bruxelles (ULB). The company develops first-in-class small-molecule antibiotics that target RelA/SpoT homolog (RSH) enzymes, which control bacterial dormancy through the ppGpp alarmone system. Santero's lead programme addresses non-cystic fibrosis bronchiectasis (NCFB) with chronic Pseudomonas aeruginosa infection, with an acute programme targeting hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and discovery-stage programmes covering prosthetic joint infection, chronic wounds, and mycobacterium infections. The company is pre-revenue and has raised over €10 million cumulatively from Newton Biocapital (lead), SFPIM, Sambrinvest, Walloon Region, Wallonie Entreprendre, and EIT Health.

The RSH enzyme inhibitor platform pursues two distinct mechanisms from a single target class: direct bactericidal activity against persistent bacteria, and resensitisation of dormant bacteria to restore efficacy of standard-of-care antibiotics. RSH enzymes are conserved across virtually all bacterial species including both Gram-positive and Gram-negative pathogens such as Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus, but absent in mammalian cells, which the company cites as a safety advantage. Santero holds exclusive licences to foundational method-of-use and screening patents from ULB providing patent protection through 2047 and is positioned for additional regulatory exclusivity through QIDP (Qualified Infectious Disease Product) designation eligibility in the US. Machine learning is integrated into compound screening and optimisation to accelerate hit-to-lead progression with a notably high hit rate.

The intended commercial model is out-licensing of programmes to large pharmaceutical companies, milestone payments during clinical development, and ultimate product sales. GTM today is enterprise- and partnership-oriented, with the CEO and CSO engaging strategic partners, pharma business development teams, and institutional investors at conferences such as BIO-Europe and the AMR Conference. Leadership was substantially rebuilt during 2024–2026 with the addition of CEO Mark Beards (former biotech CEO with QIDP and FDA pathway expertise), CSO Cuong Vuong (ex-Janssen, ex-AiCuris), COO Emilie Racine (ex-Nosopharm Head of Non-Clinical Development), and Chairman Gokhan Batur (ex-Merck Global Commercial Head, Antibiotics Portfolio). The company operates from R&D facilities at Watson & Crick Hill in Mont-Saint-Guibert, Belgium, with its registered head office in Charleroi.

Name

Santero Therapeutics

Legal name

Santero therapeutics SRL

Website

https://santero.be

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Santero Therapeutics is a Belgian preclinical biotech developing first-in-class small-molecule RSH enzyme inhibitors that disrupt bacterial dormancy, targeting chronic refractory infections including non-CF bronchiectasis, hospital-acquired pneumonia, and other indications.

Ownership category

akta.pro rank

Product category

Anti-Infective Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Antibiotic drug development
• Antimicrobial resistance therapeutics
• Preclinical biotechnology platform
• Bacterial infection treatments
• Small molecule enzyme inhibitors

Headquarters

HQ city

Charleroi

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Antibiotic Development & Licensing: Pre-revenue preclinical biotech company. As an antibiotic developer, anticipated revenue streams include licensing deals with large pharmaceutical companies, milestone payments from clinical development, and eventual product sales upon regulatory approval. The company is advancing its lead NCFB programme and acute hospital-acquired pneumonia programme through preclinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Santero Therapeutics develops first-in-class small-molecule inhibitors targeting RelA/SpoT homolog (RSH) enzymes that control bacterial dormancy, enabling two therapeutic mechanisms: direct bactericidal killing of persistent bacteria and resensitisation of dormant bacteria to existing antibiotics. The lead programme targets non-cystic fibrosis bronchiectasis (NCFB) with chronic Pseudomonas aeruginosa infection, with additional programmes for hospital-acquired bacterial pneumonia and discovery-stage chronic infections. The company is pre-revenue and preclinical, advancing toward IND-enabling studies.

Product overview

Sanero Therapeutics is a Belgian biotechnology company developing a first-in-class platform of RSH (RelA/SpoT homolog) enzyme inhibitors for chronic treatment-refractory bacterial infections. The platform enables two distinct therapeutic mechanisms: Direct Killing (small molecules with bactericidal activity that eliminate persistent bacteria) and Resensitisation (compounds that restore effectiveness of existing antibiotics). The lead programme is the NCFB Programme targeting non-cystic fibrosis bronchiectasis, with an Acute Programme targeting hospital-acquired pneumonia. The pipeline also includes discovery-stage programmes for prosthetic joint infection, chronic wound infection, and mycobacterium infections.

Differentiator

Problem solved

Functional benefit

Products and services

• RSH Enzyme Inhibitor Platform A first-in-class platform of RelA/SpoT homolog (RSH) enzyme inhibitors that target bacterial dormancy to achieve two mechanisms: direct bactericidal killing of persistent bacteria and resensitisation of dormant bacteria to existing therapies. The platform targets virtually all bacterial species while being absent in mammalian cells, and incorporates machine learning for compound screening and optimisation.
• NCFB Programme (Non-Cystic Fibrosis Bronchiectasis) Lead programme targeting reduction in exacerbation in chronic Pseudomonas aeruginosa positive non-cystic fibrosis bronchiectasis patients, addressing the persistent bacterial reservoir that drives the exacerbation cycle. NCFB affects over nine million patients in the US, Europe and China, with chronic Pseudomonas aeruginosa infection carrying three times higher mortality risk.
• Acute Programme (HABP/VABP) Programme targeting hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), an acute infection setting requiring novel antibiotic approaches to address multi-drug resistant pathogens.
• Discovery Programmes Additional indications under evaluation including prosthetic joint infection, chronic wound infection, and mycobacterium infections, addressing chronic infections caused by multi-drug resistant bacterial species including Gram-positive and Gram-negative pathogens.

Quantifiable outcome

• Over nine million NCFB patients in the US, Europe and China with significant unmet need
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Université Libre de Bruxelles (ULB)coreStrategic or Co-development PartnerSantero was founded in 2021 as a spin-off from ULB, building on nearly 20 years of foundational research into bacterial survival and persistence. Santero holds exclusive licences to foundational method and screening patents from ULB. Co-founders Professor Abel Garcia-Pino and Professor Cédric Govaerts are faculty members at ULB.
• AMPLY DiscoveryminorOthersAI/ML drug discovery company spun out of Queen's University Belfast. Santero CEO Mark Beards serves concurrently as Non-Executive Chair of AMPLY Discovery.
• PFU TherapeuticsminorOthersNext-generation RNA therapeutics company focused on rare diseases. Santero CEO Mark Beards serves concurrently as Chair of PFU Therapeutics.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nosopharm: French preclinical/early-clinical antibiotic developer of the Odilorhabdin programme. Highly comparable to Santero in size, stage, AMR focus, and origin; Santero's COO Emilie Racine was previously Head of Non-Clinical Development at Nosopharm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/santero-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santero Therapeutics